Patent SG-11201906163T-A (SG)
Title: Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus
Inventor: MOUSSA ADEL
IPC: C07F9/6521
Filed: 2018-01-31
Abstract: 2 150 100 0 (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 09 August 2018 (09.08.2018) WIPO I PCT o mono VIII °nolo Ho Ho Em 100 Ho 110 111110 oimIE (10) International Publication Number WO 2018/144640 Al (51) International Patent Classification: CO7F 9/6521 (2006.01) CO7F 9/6558 (2006.01) (21) International Application Number: PCT/US2018/016301 (22) International Filing Date: 31 January 2018 (31.01.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/453,437 01 February 2017 (01.02.2017) US 62/469,912 10 March 2017 (10.03.2017) US 62/488,366 21 April 2017 (21.04.2017) US 62/575,248 20 October 2017 (20.10.2017) US (71) Applicant: ATEA PHARMACEUTICALS, INC. [US/US]; 125 Summer Street, Boston, MA 02110 (US). (72) Inventors: MOUSSA, Adel; C/o Atea Pharmaceuticals, Inc., 125 Summer Street, Boston, MA 02110 (US). SOM- MADOSSI, Jean-Pierre; C/o Atea Pharmaceuticals, Inc., 125 Summer Street, Boston, MA 02110 (US). (74) Agent: BELLOWS, Brent, R. et al.; Knowles Intellectu- al Property Strategies, LLC, 400 Perimeter Center Terrace, Suite 200, Atlanta, GA 30346 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). = (54) Title: NUCLEOTIDE HEMI-SULFATE SALT FOR THE TREATMENT OF HEPATITIS C VIRUS (57) : A hemi-sulfate salt of the structure: [Formula should be inserted here] to treat a host infected with hepatitis C, as well as phar- maceutical compositions and dosage forms, including solid dosage forms, thereof. la lb 2a lb 3a 4a 4d 0 CbrnPd 1 18.3 21.5 13.5 9.6 17.2 22.1 23.9 n 5Aosta* 132 167 50.7 76.7 195 177 265 W O 20 18/ 1446 40 Al FIG. 24 [Continued on next page] WO 2018/144640 Al 1#110figinigE1013010HOEHINHOEMEEN Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(11)) as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: — with international search report (Art. 21(3))